 Enoxaparin
"Enoxaparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)
| Descriptor ID |
D017984
|
| MeSH Number(s) |
D09.698.373.400.300.200
|
| Concept/Terms |
PK-10,169- PK-10,169
- PK 10,169
- PK10,169
- PK-10169
- PK 10169
- PK10169
|
Below are MeSH descriptors whose meaning is more general than "Enoxaparin".
Below are MeSH descriptors whose meaning is more specific than "Enoxaparin".
This graph shows the total number of publications written about "Enoxaparin" by people in this website by year, and whether "Enoxaparin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 2 | 3 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2020 | 3 | 1 | 4 | | 2021 | 3 | 2 | 5 | | 2022 | 2 | 3 | 5 | | 2023 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Enoxaparin" by people in Profiles.
-
Vaughn AE, Hall JK, Harrison ML, Klein G, Diaz-Miron J, Yi JA, Acker SN. Practice patterns in the management of pediatric iliofemoral arterial thrombosis. Surgery. 2023 10; 174(4):940-945.
-
Cho YW, Scrushy M, Zhu M, DeAtkine E, Zhu M, Wan B, Fesmire A, Cripps M, Park C. Early administration of high dose enoxaparin after traumatic brain injury. Eur J Trauma Emerg Surg. 2023 Oct; 49(5):2295-2303.
-
Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. J Urol. 2022 10; 208(4):886-895.
-
Borst JM, Modi RN, Kirchberg TN, Box K, Smith AM, Godat LN, Doucet JJ, Costantini TW, Berndtson AE. You're never too old for optimal venous thromboembolism prophylaxis: Re-thinking current trauma guidelines. Thromb Res. 2022 10; 218:186-188.
-
Whipple MO. Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727. J Vasc Nurs. 2022 09; 40(3):155-156.
-
Bellfi LT, Zimmerman SA, Boudreau R, Mosier W, Smith A, Rueb N, Hunt JP, Stuke L, Greiffenstein P, Schoen J, Marr A. Impact of Increased Enoxaparin Dosing on Anti-Xa Levels for Venous Thromboembolism Prophylaxis in Trauma Patients. Am Surg. 2022 Sep; 88(9):2158-2162.
-
Modi RN, Borst JM, Kirchberg TN, Box K, Smith AM, Godat LN, Doucet JJ, Costantini TW, Berndtson AE. One size does not fit all: Sex bias in pharmacologic venous thromboembolism prophylaxis. J Trauma Acute Care Surg. 2023 01 01; 94(1):78-85.
-
Bai X, Buckle AM, Vladar EK, Janoff EN, Khare R, Ordway D, Beckham D, Fornis LB, Majluf-Cruz A, Fugit RV, Freed BM, Kim S, Sandhaus RA, Chan ED. Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. Sci Rep. 2022 03 25; 12(1):5207.
-
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 12 01; 181(12):1612-1620.
-
Schroeppel TJ, Clement LP, Douville AA, Schmoekel NH, Stassinopoulos J, Decker C, Stillman ZE, Rodriquez J, Brockman VP, Hennessy E, Heise H, Khan AD. Time is of the Essence: Impact of a More Aggressive Chemical Venous Thromboembolism Prophylaxis Regimen on Trauma Patients. Am Surg. 2022 Mar; 88(3):455-462.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|